HRP20161520T1 - Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju - Google Patents

Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju Download PDF

Info

Publication number
HRP20161520T1
HRP20161520T1 HRP20161520TT HRP20161520T HRP20161520T1 HR P20161520 T1 HRP20161520 T1 HR P20161520T1 HR P20161520T T HRP20161520T T HR P20161520TT HR P20161520 T HRP20161520 T HR P20161520T HR P20161520 T1 HRP20161520 T1 HR P20161520T1
Authority
HR
Croatia
Prior art keywords
sialylation
alpha
recombinant fsh
rfsh
cell line
Prior art date
Application number
HRP20161520TT
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161520(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP20161520T1 publication Critical patent/HRP20161520T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

1. Rekombinantni FSH (rFSH) uključujući α2,3- i a2,6-sialilaciju naznačen time da je 80% ili više od ukupne sialilacije α2,3-sialilacija i pri čemu od 5% do 20% od ukupne sialilacije je α2,6-sialilacija.
2. Rekombinantni FSH prema zahtjevu 1 naznačen time da je eksprimiran u ljudskoj staničnoj liniji.
3. Farmaceutski pripravak naznačen time da sadrži rFSH prema zahtjevu 1 ili zahtjevu 2.
4. Farmaceutski pripravak prema zahtjevu 3 naznačen time da dodatno sadrži hCG i/ili LH.
5. Farmaceutski pripravak prema zahtjevu 3 ili 4 naznačen time da je za uporabu za liječenje neplodnosti.
6. Postupak proizvodnje rFSH prema bilo kojem od zahtjeva 1 ili 2 naznačen time da sadrži korak proizvodnje ili eksprimiranja rFSH u ljudskoj staničnoj liniji.
7. Postupak prema zahtjevu 6 naznačen time da je stanična linija izmijenjena upotrebom α2,3-sialiltransferaze i/ili α2,6-sialiltransferaze.
HRP20161520TT 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju HRP20161520T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
HRP20161520T1 true HRP20161520T1 (hr) 2016-12-30

Family

ID=39717519

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2014-06-09 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju
HRP20161520TT HRP20161520T1 (hr) 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2014-06-09 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Country Status (29)

Country Link
US (5) US8951967B2 (hr)
EP (7) EP3045471B1 (hr)
JP (7) JP2011519359A (hr)
KR (5) KR20180095140A (hr)
CN (3) CN102066414A (hr)
AR (1) AR071479A1 (hr)
AU (5) AU2009237479B2 (hr)
BR (1) BRPI0910461B8 (hr)
CA (1) CA2725257A1 (hr)
CY (1) CY1115413T1 (hr)
DK (4) DK3144318T3 (hr)
ES (3) ES2610277T3 (hr)
FR (1) FR17C1020I2 (hr)
HK (2) HK1146284A1 (hr)
HR (3) HRP20140535T1 (hr)
HU (5) HUE030652T4 (hr)
IL (2) IL208538A (hr)
LT (4) LT3045471T (hr)
MX (3) MX2010011343A (hr)
NO (2) NO2017025I1 (hr)
NZ (1) NZ588381A (hr)
PL (4) PL2268666T3 (hr)
PT (4) PT2808340T (hr)
RU (3) RU2537268C2 (hr)
SA (1) SA109300228B1 (hr)
SI (4) SI3045471T1 (hr)
TW (1) TWI488640B (hr)
WO (1) WO2009127826A1 (hr)
ZA (1) ZA201007373B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
ES2547233T5 (es) 2010-09-29 2024-03-27 Ferring Bv Composición para su uso en el tratamiento de la esterilidad
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
DK3662925T3 (da) 2015-04-17 2021-06-28 Ferring Bv Sammensætning, der omfatter fsh, til behandling af infertilitet
RU2719468C2 (ru) 2015-06-26 2020-04-17 Ферринг Б.В. Способы очистки и/или вирусной инактивации
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
MX2020002235A (es) 2017-09-01 2020-07-20 Ferring Bv Composicion para la estimulacion ovarica controlada.
TW201945024A (zh) 2018-04-30 2019-12-01 荷蘭商菲林公司 用於經控制之卵巢刺激的組成物
TW202027780A (zh) 2018-10-17 2020-08-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
KR100449181B1 (ko) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
EA012340B1 (ru) 2001-10-29 2009-10-30 Круселл Холланд Б.В. Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
NZ533124A (en) 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US8431355B2 (en) 2004-02-04 2013-04-30 Universite De Provence Aix-Marseille 1 Process for screening glycoform-specific antibodies
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
ES2547233T5 (es) 2010-09-29 2024-03-27 Ferring Bv Composición para su uso en el tratamiento de la esterilidad
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
SI3045471T1 (sl) 2017-07-31
EP3144318B1 (en) 2020-09-23
US9546204B2 (en) 2017-01-17
US20150065695A1 (en) 2015-03-05
HUS1700024I1 (hu) 2017-06-28
US20110105398A1 (en) 2011-05-05
JP6486310B2 (ja) 2019-03-20
AU2017204259B2 (en) 2017-08-17
PL2808340T3 (pl) 2017-02-28
US20180079794A1 (en) 2018-03-22
FR17C1020I2 (fr) 2020-04-10
HK1199039A1 (en) 2015-06-19
PT3045471T (pt) 2017-06-14
EP2808340A1 (en) 2014-12-03
EP4015527A1 (en) 2022-06-22
IL208538A (en) 2014-03-31
NZ588381A (en) 2012-05-25
LT2808340T (lt) 2016-11-10
US9771407B2 (en) 2017-09-26
RU2537268C2 (ru) 2014-12-27
EP2808340B1 (en) 2016-08-17
IL230571A (en) 2015-11-30
US10995128B2 (en) 2021-05-04
WO2009127826A1 (en) 2009-10-22
US20210332099A1 (en) 2021-10-28
TW200948378A (en) 2009-12-01
BRPI0910461B1 (pt) 2021-02-23
KR20160056960A (ko) 2016-05-20
SI2808340T1 (sl) 2016-12-30
JP2018021037A (ja) 2018-02-08
NO2017025I1 (no) 2017-06-06
US11952407B2 (en) 2024-04-09
AU2017225020A1 (en) 2017-09-28
KR20190092608A (ko) 2019-08-07
ZA201007373B (en) 2011-06-29
PT2268666E (pt) 2014-06-25
DK3045471T3 (en) 2017-06-26
AU2017204258A1 (en) 2017-07-20
RU2014141994A (ru) 2016-05-10
ES2629392T3 (es) 2017-08-09
AU2017225020B2 (en) 2019-11-14
TWI488640B (zh) 2015-06-21
KR20170110741A (ko) 2017-10-11
EP2722339A1 (en) 2014-04-23
RU2745557C3 (ru) 2021-12-10
PT2808340T (pt) 2016-11-21
JP7316905B2 (ja) 2023-07-28
HUE030652T4 (en) 2017-09-28
DK2268666T3 (da) 2014-05-12
PT3144318T (pt) 2020-11-04
CA2725257A1 (en) 2009-10-22
SI2268666T1 (sl) 2014-07-31
JP2020040956A (ja) 2020-03-19
JP2015120696A (ja) 2015-07-02
JP6762916B2 (ja) 2020-09-30
AU2009237479A1 (en) 2009-10-22
RU2014141994A3 (hr) 2018-05-28
LTPA2017018I1 (lt) 2017-06-26
MX355457B (es) 2018-04-19
EP2268666B1 (en) 2014-03-12
EP3098234A1 (en) 2016-11-30
EP3045471A1 (en) 2016-07-20
JP2024038000A (ja) 2024-03-19
CY1115413T1 (el) 2017-01-04
AU2014203277A1 (en) 2014-07-24
RU2745557C1 (ru) 2021-03-29
PL2268666T3 (pl) 2014-08-29
JP2017060476A (ja) 2017-03-30
ES2468318T3 (es) 2014-06-16
JP2022031652A (ja) 2022-02-22
HRP20170958T1 (hr) 2017-09-22
RU2682270C2 (ru) 2019-03-18
AU2014203277B2 (en) 2017-04-06
SA109300228B1 (ar) 2014-04-08
LT3045471T (lt) 2017-07-10
MX348622B (es) 2017-06-22
NO2017050I1 (no) 2017-09-28
HK1146284A1 (en) 2011-05-20
EP3045471B1 (en) 2017-03-29
HUE030652T2 (en) 2017-05-29
CN105906702A (zh) 2016-08-31
EP3144318A1 (en) 2017-03-22
KR20110005863A (ko) 2011-01-19
LTPA2017029I1 (lt) 2017-10-10
SI3144318T1 (sl) 2020-12-31
US20160347811A1 (en) 2016-12-01
KR102108377B1 (ko) 2020-05-08
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
BRPI0910461A2 (pt) 2018-03-27
AU2014203277C1 (en) 2017-07-27
AU2009237479B2 (en) 2014-05-15
AR071479A1 (es) 2010-06-23
AU2017204258B2 (en) 2017-08-17
RU2010141908A (ru) 2012-05-27
DK2808340T3 (en) 2016-12-05
US8951967B2 (en) 2015-02-10
MX2010011343A (es) 2011-01-20
JP2011519359A (ja) 2011-07-07
PL3144318T3 (pl) 2021-02-08
CN105906703A (zh) 2016-08-31
EP2268666A1 (en) 2011-01-05
AU2017204259A1 (en) 2017-07-20
HUS1700036I1 (hu) 2017-10-30
IL208538A0 (en) 2010-12-30
CN102066414A (zh) 2011-05-18
FR17C1020I1 (hr) 2020-04-10
HUE033830T2 (en) 2018-01-29
DK3144318T3 (da) 2020-12-07
BRPI0910461B8 (pt) 2021-05-25
HUS1700025I1 (hu) 2017-06-28
BRPI0910461A8 (pt) 2018-10-16
KR20180095140A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
HRP20161520T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
JP2018021037A5 (hr)
IL218989A (en) Processed 3-phenylpropionic acids, their process, their preparations and their use
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
IL238840B (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and their use in the preparation of drugs for the treatment of thrombocytopenia
HRP20220500T1 (hr) Pripravci i postupci za glikoziliranje proteina
MY158438A (en) Antibodies against human angiopoietin 2
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
EP2298471A4 (en) COMPOSITE SILVER NANOPARTICLES, COMPOSITE SILVER NANOPATHES, AND METHOD FOR PRODUCING THE SAME, PRODUCTION APPARATUS, CONJUGATION METHOD, AND METHOD OF MANUFACTURING
IL212568A (en) Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals
ATE541863T1 (de) Redispergierbare nanopartikel
PL2352386T3 (pl) Sposób wytwarzania związku kwasu n-masłowego w postaci mikrokapsułkowanej do spożycia przez zwierzęta lub ludzi
WO2011062437A3 (ko) 고나도트로핀 방출 호르몬 수용체 길항제, 이의 제조방법 및 이를 함유하는 약제학적 조성물
WO2008019850A3 (de) Vorrichtung zum bearbeiten und/oder handling von gegenständen
WO2009153017A3 (de) Vorrichtung zur serienmässigen gefriertrocknung
ATE435016T1 (de) Im mund dispergierbare domperidon-tabletten
SI2247369T1 (sl) Struktura katalizatorja titanovega dioksida za postpoke do 1000 C in njegova izdelava
JP2010001264A5 (hr)
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
EP2266619A4 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
CL2008000906A1 (es) Compuestos derivados de benzimidazol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por la actividad del receptor 2 cannabinoide.
IT1393945B1 (it) Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
RS54214B1 (en) MIXTURE FOR USE IN THE TREATMENT OF INFERTILITY
HRP20201688T1 (hr) Rekombinantni fsh koji ukjlučuje alfa 2,3- i alfa 2,6-sialilaciju
ATE481393T1 (de) Neue cycloalkyl-benzothiadiazin-derivate, ihr herstellungsverfahren und die pharmazeutischen zusammensetzungen, die sie enthalten